PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)
暂无分享，去创建一个
J. Bono | M. Wongchenko | A. Font | S. Bracarda | C. Massard | U. Giorgi | S. Gendreau | V. Jinga | R. Riisnaes | D. Rodrigues | I. Kocák | D. Maslyar | J. A. Arija | K. Shih | G. Rădăvoi | Wei Yu | W. Chan | Liangxuan Zhang